These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 12624548)

  • 1. Long-term administration of intravaginal dehydroepiandrosterone on regression of low-grade cervical dysplasia--a pilot study.
    Suh-Burgmann E; Sivret J; Duska LR; Del Carmen M; Seiden MV
    Gynecol Obstet Invest; 2003; 55(1):25-31. PubMed ID: 12624548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel dehydroepiandrosterone troche supplementation improves the serum androgen profile of women undergoing in vitro fertilization.
    Keane KN; Hinchliffe PM; Namdar N; Conceicao JL; Newsholme P; Yovich JL
    Drug Des Devel Ther; 2015; 9():5569-78. PubMed ID: 26487801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral dehydroepiandrosterone (DHEA) replacement therapy in women with Addison's disease.
    Gebre-Medhin G; Husebye ES; Mallmin H; Helström L; Berne C; Karlsson FA; Kämpe O
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):775-80. PubMed ID: 10848883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks.
    Martel C; Labrie F; Archer DF; Ke Y; Gonthier R; Simard JN; Lavoie L; Vaillancourt M; Montesino M; Balser J; Moyneur É;
    J Steroid Biochem Mol Biol; 2016 May; 159():142-53. PubMed ID: 26972555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Adrenopause and dehydroepiandrosterone: pharmacological therapy versus replacement therapy].
    Römmler A
    Gynakol Geburtshilfliche Rundsch; 2003 Apr; 43(2):79-90. PubMed ID: 12649580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology.
    Labrie F; Bélanger A; Cusan L; Candas B
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2403-9. PubMed ID: 9253308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum steroids remain within the same normal postmenopausal values during 12-month intravaginal 0.50% DHEA.
    Ke Y; Gonthier R; Simard JN; Archer D; Lavoie L; Martel C; Vaillancourt M; Labrie F
    Horm Mol Biol Clin Investig; 2015 Dec; 24(3):117-29. PubMed ID: 26509785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause.
    Stomati M; Monteleone P; Casarosa E; Quirici B; Puccetti S; Bernardi F; Genazzani AD; Rovati L; Luisi M; Genazzani AR
    Gynecol Endocrinol; 2000 Oct; 14(5):342-63. PubMed ID: 11109974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression.
    Arlt W; Justl HG; Callies F; Reincke M; Hübler D; Oettel M; Ernst M; Schulte HM; Allolio B
    J Clin Endocrinol Metab; 1998 Jun; 83(6):1928-34. PubMed ID: 9626121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical studies on intravaginal administration of CDDP for dysplasia, carcinoma in situ and microinvasive carcinoma of the uterine cervix].
    Nakayama K; Sano Y; Endo Y; Sato H; Ohyama T; Yamaguchi M
    Nihon Sanka Fujinka Gakkai Zasshi; 1992 Feb; 44(2):208-14. PubMed ID: 1545173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Supplementation with DHEA: effect on muscle size, strength, quality of life, and lipids.
    Dayal M; Sammel MD; Zhao J; Hummel AC; Vandenbourne K; Barnhart KT
    J Womens Health (Larchmt); 2005 Jun; 14(5):391-400. PubMed ID: 15989411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months.
    van Vollenhoven RF; Morabito LM; Engleman EG; McGuire JL
    J Rheumatol; 1998 Feb; 25(2):285-9. PubMed ID: 9489820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Panhypopituitarism as a model to study the metabolism of dehydroepiandrosterone (DHEA) in humans.
    Young J; Couzinet B; Nahoul K; Brailly S; Chanson P; Baulieu EE; Schaison G
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2578-85. PubMed ID: 9253337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restoring testosterone levels by adding dehydroepiandrosterone to a drospirenone containing combined oral contraceptive: I. Endocrine effects.
    Zimmerman Y; Foidart JM; Pintiaux A; Minon JM; Fauser BC; Cobey K; Coelingh Bennink HJ
    Contraception; 2015 Feb; 91(2):127-33. PubMed ID: 25604900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations in DHEA metabolism in schizophrenia: two-month case-control study.
    Ritsner M; Gibel A; Ram E; Maayan R; Weizman A
    Eur Neuropsychopharmacol; 2006 Feb; 16(2):137-46. PubMed ID: 16139994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex, age, pubertal development and use of oral contraceptives in relation to serum concentrations of DHEA, DHEAS, 17α-hydroxyprogesterone, Δ4-androstenedione, testosterone and their ratios in children, adolescents and young adults.
    Søeborg T; Frederiksen H; Mouritsen A; Johannsen TH; Main KM; Jørgensen N; Petersen JH; Andersson AM; Juul A
    Clin Chim Acta; 2014 Nov; 437():6-13. PubMed ID: 24976611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women.
    Portman DJ; Labrie F; Archer DF; Bouchard C; Cusan L; Girard G; Ayotte N; Koltun W; Blouin F; Young D; Wade A; Martel C; Dubé R;
    Menopause; 2015 Dec; 22(12):1289-95. PubMed ID: 25968836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of a two-week physiological dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly women and men.
    Wolf OT; Neumann O; Hellhammer DH; Geiben AC; Strasburger CJ; Dressendörfer RA; Pirke KM; Kirschbaum C
    J Clin Endocrinol Metab; 1997 Jul; 82(7):2363-7. PubMed ID: 9215320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration.
    Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Bérubé R; Bélanger P; Berger L; Gilbert L; Martel C; Balser J
    Menopause; 2009; 16(5):897-906. PubMed ID: 19436226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels of sex steroids and metabolites following 12 weeks of intravaginal 0.50% DHEA administration.
    Ke Y; Labrie F; Gonthier R; Simard JN; Bergeron D; Martel C; Vaillancourt M; Montesino M; Lavoie L; Archer DF; Balser J; Moyneur E;
    J Steroid Biochem Mol Biol; 2015 Nov; 154():186-96. PubMed ID: 26291918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.